Kornimate/medical-research-clean huggingface dataset:
prognostic and predictive value of he4 biomarker in metastatic ovarian cancer

Conditions: Metastatic Ovarian Cancer

Summary: he4 is a new marker that could improve the detection of ovarian cancer. the he4 assay may have an advantage over the ca-125 assay in that it is less frequently positive in patients with non malignant disease. since the evaluation of he4 for detection and diagnosis of ovarian cancer is well known, the behaviour of the marker during chemotherapy and follow-up period after treatment in metastatic ovarian cancer should be studied. it could be used in patient with non ca-125 secretary tumors. prognosis and predictive value of he4 should be compared with information provided by ca-125. the kinetics of he4 values after treatment should be also analysed to determine the role that he4 could play in the detection of recurrences during the follow-up of metastatic patients.


Eligibility criteria:
inclusion criteria: * histologically proved epithelial ovarian cancer (serous, mucinous, clear cell, endometrioid, undifferentiated type) * recurrence of anytime necessitating a new line of chemotherapy * patient having received adjuvant chemotherapy * informed consent signed prior any study specific procedures exclusion criteria: * more than 3 lines of chemotherapy * pregnancy or breastfeeding * history of other cancers within the past 5 years (except curatively treated non-melanoma skin cancer and in situ cervical cancer) * psychological, social, geographical disorders or any other condition that would preclude study compliance (treatment modalities and study follow-up).

Keywords: ovarian cancer biomarker metastatic
the comparison of effectivity therapy by hilt and trt in muscle hypertonus

Conditions: Muscle Tone Abnormalities; Muscle Spasm

Summary: comparing the effect of high-intensity laser therapy (hilt) and targeted radiofrequency therapy (trt) on muscle tone in the cervical and thoracic regions. the research aims to determine the effectiveness of the effect of novel physical therapy on the change of muscle tone in the cervical and thoracic region. this is an intervention experiment applied to a group of 60 probands.

approximately 60 probands, aged 18-60 years, with no gender preference, will be recruited from patients of an unnamed healthcare facility based on their voluntary participation while receiving a current indication for physiotherapy with a diagnosis of cb syndrome. subjects will be randomized into three groups. the first probands (n'20) will have hilt applied bilaterally to the mm. scalene, m.levator scapulae and m.trapezius pars descendens. the second group (n'20) will have trt applied bilaterally to mm. scalene, m.levator scapulae and m.trapezius pars descendens. no physical therapy or physiotherapy will be used for the third group (n'20) for the duration of the study. subjects will be examined and treated three times a week for a total of 6 times. the effect of each type of therapy will be demonstrated palpationally and subjectively using an analogue pain scale and an algometer. the obtained results will be further statistically processed.

Eligibility criteria:
inclusion criteria: * the presence of hypertonus in the mm.scalene, m.levator scapulae and m.trapezius pars descendens bilaterally * tension demonstrated by palpation and subjective assessment of the patient on an analogue pain scale exclusion criteria: * individuals with acute or infectious disease * probands psychiatric diagnoses * patients with cancers * problems with skin integrity disorders * other contraindications to the use of hilt and trt

Keywords: muscle tone hilt trt scalene muscle levator scapulae trapezius muscle
tms alteration of the reward positivity

Conditions: Anhedonia

Summary: the aim of this proposal is to demonstrate that stimulation of different brain regions differently affects the electroencephalographic feature known as the reward positivity (rewp).

the aim of this proposal is to demonstrate that stimulation of different brain regions differently affects the electroencephalographic feature known as the reward positivity (rewp). the rewp is a sensitive and specific biomarker of reward receipt. this proposal will advance a causal test of the hypothesis that there are two major sources of variance that contribute to this brain response: a dorsal midline contribution to information encoding and a ventral midline contribution that is modulated by affect. together, these findings will reveal how the rewp acts to blend multiple aspects of value together in the service of motivated learning. the objective of this proposal is to gather pilot data to demonstrate the feasibility of using transcranial magnetic stimulation (tms) to perturb idiosyncratically-defined (fmri-based) dorsal or ventral targets in order to causally test the hypothesis that these different sources contribute different types of variance to the rewp. tms double cone deep coil stimulation should diminish +rpe encoding in the rewp when compared to sham. tms figure-8 coil stimulation should diminish affective modulation of rewp amplitude when compared to sham.

Eligibility criteria:
inclusion criteria: • men or women aged 18-30 exclusion criteria: * participants unwilling or unable to give informed consent * presence of other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study * meg/mri contraindications * history of psychosis * not fluent in english
vertebral marrow attention trial (vmat)

Conditions: Lung Cancer

Summary: the purpose of this study is to see whether designing radiation to spare the vertebral bone marrow can limit the rates of lymphopenia during standard of care chemoradiation therapy and in the time to count recovery in the ensuing weeks. secondary endpoints will examine whether this leads to improved disease control whether this is predictive of improved clinical outcomes such as rates of local recurrence (lr), metastasis free survival (mfs), overall survival (os), and progression free survival (pfs) which will be followed prospectively up to 5 years.


Eligibility criteria:
inclusion criteria: * adult patient \> 18 years * patients with ajcc (american joint committee on cancer) 8 t1-t4, n1-n3, m0 stage iiia-iiic nsclc (non small cell lung cancer) * patients with oligometastatic disease stage iv, m1 disease, in which definitive concurrent chemoradiotherapy to the thorax is planned * cbc/cmp within these limits * absolute lymphocyte count\>500/ml * hemoglobin\>8 g/dl * ast (aspartate aminotransferase)/alt (alanine transaminase) \<2.5 times of uln * eastern cooperative oncology group (ecog) 0-2 exclusion criteria: * history of thoracic irradiation * history of palliative radiation for the current malignancy under consideration * patients not being treated with definitive standard of care to the chest * history of bone marrow disease and or leukemia * history of prior cytotoxic chemotherapy for a disease other than for the current malignancy * polymetastatic disease, defined here as ≥3 or more extrathoracic metastases * administration of concurrent immunotherapy during radiation therapy, either as part of another clinical trial or otherwise
sequential and maintenance icotinib plus chemotherapy versus icotinib maintenance after chemotherapy in advanced nsclc

Conditions: EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma

Summary: this randomised, controlled, open-label, prospective trial is designed to assess the efficacy and safety of icotinib maintenance therapy after sequential icotinib plus chemotherapy versus icotinib maintenance therapy after chemotherapy in stage iiib/iv non-small cell lung cancer patients with egfr mutation.


Eligibility criteria:
inclusion criteria: * stage iv or iiib advanced non-small cell lung cancer patients * positive egfr mutation * non-progressive disease after first-line gemcitabine/cisplatin therapy * measurable lesion according to recist 1.1 with at least one measurable lesion exclusion criteria: * previous anti-egfr (epidermal growth factor receptor) monoclonal antibody or small molecular agent such as gefitinib, erlotinib and so on * patients with wild-type egfr * evidence of interstitial lung diseases * severe hypersensitivity to icotinib or any of the excipients of this product. * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
hybrid- nature: recovering from work through nature experiences

Conditions: Physiological Recovery; Psychological Recovery; Restorative Experiences

Summary: the research examines employees' recovery from work stress during visits in nearby nature and when viewing virtual nature with virtual reality (vr) goggles. the research provides information on the physiological and psychological recovery of employees who do remote or hybrid work. recovery is analysed with qualitative and quantitative methods including firstbeat life measurements, surveys and interviews. the results can be used in workplaces to develop operating models to promote well-being in remote and hybrid work. the research generates new understanding on how employees' recovery can be supported by means of virtual nature tourism services.

an intervention study with a cross-over research design will be conducted among a sample of 60 employees who do remote or hybrid work. the intervention phase lasts in total of four weeks. during the first week (control phase), the participants continue their daily routine as normal. during the second week of the intervention, a half of the participants are randomised to visit a nearby natural area after finishing work (exposure to nearby nature). the other half of the participants are randomised to view virtual nature videos with vr goggles after finishing work (exposure to virtual nature). on the third week of the intervention, the participants complete nature exposure the other way around. that is, those participants who took part first in exposure to nearby nature will view virtual nature, and vice versa. on the fourth week of the intervention, the participants take part in a semi-structured focus group interview. recovering from work in nearby nature and virtual nature is examined through multidisciplinary perspectives of health, well-being, and tourism. the aim of the research is to find new ways of promoting work stress recovery, psychological detachment and restoration among employees when they are making the transition between work time and personal time. these research findings are particularly relevant for fields in which there has been a growing trend for remote or hybrid work. this research is funded by the finnish work environment fund (project number: 220076).

Eligibility criteria:
inclusion criteria: * employees who do remote or hybrid work * able to communicate adequately in finnish in order to participate exclusion criteria: * no exclusion criteria for study participation. * firstbeat life analyses are only available for participants who identify themselves on the basis of biological sex of female or male. * firstbeat life analyses might be unreliable for participants with some health-related issues (e.g., pacemaker, heart transplantation, complex cardiac disease, persistent atrial fibrillation or flutter, or uncontrolled thyroid disease) and therefore measurements will not be performed for them as a part of this research.

Keywords: recovery nature employees work stress occupational well-being virtual reality
effect of the consumption of a fermented dairy product enriched with plant sterols

Conditions: Mild Hypercholesterolemic Subjects

Summary: the purpose of this study is to investigate the cholesterol lowering effect of a drinkable low fat fermented milk enriched with plant sterols after 3 weeks of daily consumption in midly hypercholesterolemic people.


Eligibility criteria:
inclusion criteria: * male/female subject, aged from 18 to 75,with bmi between 18,5 and 30 kg/m², with ldl-cholesterol blood level between 130 mg/dl to 190 mg/dl without statin therapy. * subject accepting to follow the dietary recommendations advisable for hypercholesterolemic subject. * subject used to consume dairy products. * for female subjects: effective contraceptive methods used. * subject having given written consent to take part in the study. exclusion criteria: * subject with blood triglycerides levels above 350 mg/dl. * subject having experienced any cardiovascular event in the last 6 months. * subject having sitosterolemia. * subject taking any hypocholesterolemic treatment drugs. * intake of blood lipid-regulating supplementation of blood lipid-regulating dietary supplements or functional food during the last 2 weeks before study start. * diabetic subject (type i and type ii). * subject smoking strictly more than 10 cigarettes / day. * subject with heavy alcohol intake (\> 40 g / day for men ; \> 30 g / day for women). * subject presenting known allergy or hypersensitivity to milk proteins.subject with known soy allergy. * subject refusing to stop the consumption of plant sterols-enriched products if any during the study (other than the studied product). * subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters. * subject receiving a transplant and under immunosuppressor treatment. * subject currently involved in a clinical trial or in an exclusion period following participation in another clinical trial. * subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject. * subject with any kind of disease likely to interfere with the evaluation of efficiency or safety of the product. * for female subject: pregnancy, breast feeding or intention to be pregnant during the study. * for female subject: subject likely to change her contraceptive method during the study.

Keywords: plant sterols - hypercholesterolemia - diet - dairy
biomarker predictors of memantine sensitivity in patients with alzheimer's disease

Conditions: Alzheimer Disease

Summary: the effects of the medication, memantine, on brain functions and the symptoms of alzheimer's disease will be tested


Eligibility criteria:
inclusion: 1. alzheimer's disease research center-confirmed diagnosis of ad 2. mini-mental state examination (mmse) score 10-22 or a montreal cognitive assessment (moca) score of 15-24 3. age 50-83 y 4. knowledgeable caregiver 5. ambulatory 6. medically stable; 7. audiometric testing (detection \< 40 db(a) at 1000 hz) 8. informed consent exclusion: 1. active systemic illness (e.g. heart disease, liver failure, renal insufficiency, cancer, hiv, tuberculosis, hepatitis c) 2. current psychiatric or neurologic illness other than ad 3. history of vascular disease, myocardial infarction, cerebrovascular accidents, transient ischemic attack, seizure, head injury with loss of consciousness; substance dependence (including alcohol and opioid) 4. past treatment with memantine; unable to tolerate acetylcholinesterase inhibitor 5. investigational drug treatment \< 30 d of screening 6. current meds: amantadine, riluzole, other pro-cognitive medication, opioids 7. positive urine toxicology for non-prescribed psychoactive substance 8. actively enrolled in cognitive remediation therapy

Keywords: alzheimer's disease alzheimer disease alzheimer ad alzheimer's
efficacy of botulinum toxin in temporomandibular disorders

Conditions: Temporomandibular Joint Disorder Bilateral

Summary: temporomandibular disorders (tmds) represent a multifactorial pathological group that gives rise to a varied and complex symptomatology that includes decreased jaw movement, muscle and joint pain, joint crepitation and limitation or functional deviation of the jaw opening. all this is sometimes accompanied by headache and other painful symptoms in the neck musculature, incapacitating for many patients and at considerable public health expense. intramuscular and intra-articular injections of botulinum toxin are a simple treatment that has proven to be effective in the treatment of the painful symptoms of these disorders, being a therapeutic option in situations of failure of conventional treatments, without presenting adverse effects. our study presents the preliminary results of twenty patients treated with this therapy

tmds are a common pathology affecting up to 70% of the population, with a maximum incidence in young patients. we used a sample of twenty patients recruited in the maxillofacial surgery service of the university hospital of salamanca (spain), who met the inclusion criteria, with unilateral painful symptomatology of more than three months duration. all patients were randomly treated by intramuscular and intra-articular injections of btx (100 u) in 8 predetermined points. pain symptomatology was assessed at the different locations, together with joint symptomatology, at baseline and 6 weeks after treatment. adverse effects were also evaluated. in 85% of the patients, pain on oral opening improved and 90% showed improvement of pain on mastication. a 75% of the patients reported improvement in joint clicking/noise. headaches improved or disappeared in 70% of the patients treated. despite the limitations of the study and the preliminary results, intramuscular and intra-articular infiltrations with btx were effective in the treatment of symptoms associated with tmds, with minimal adverse effects.

Eligibility criteria:
inclusion criteria: * the study included patients diagnosed with tmds, according to the established diagnostic criteria, aged between 18 and 69 years (both included) and with unilateral painful symptomatology of more than three months' duration. exclusion criteria: * patients previously treated with surgery/arthrocentesis of the tmj; patients treated in the last six months with surgery in the cervicofacial region; patients who, at the time of inclusion in the study, were being treated in a "pain unit" and patients who had previously received treatment with btx.

Keywords: botulinum toxin temporomandibular joint disorders masticatory disfunction syndrome randomized clinical trial
pointing: clinical cohort study of patients with melanoma and nsclc receiving checkpoint inhibitors

Conditions: Melanoma; Non-Small Cell Lung Cancer

Summary: this is a two-center, prospective continuously accruing longitudinal cohort study in patients with non-small cell lung carcinoma (nsclc) or metastatic melanoma eligible for standard anti-pd-1 antibody treatment. the data from this prospective longitudinal cohort will be used in the pointing (towards patient -tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging) kwf kankerbestrijding project (wp4). the goal of this project is to develop a multifaceted predictive signature, by using new techniques on tumor characteristics before and during treatment with immune therapy. to do so, researchers will use the 'omics' approach. by combining molecular omics comprising genomics, transcriptomics, proteomics with radiomics and molecular imaging a set of factors will arise which can accurately predict the outcome of the treatment. participants in this cohort will undergo tumor biopsies, venous blood sampling and feces sampling before, during and at the end of standard anti-pd-1 antibody treatment. also, data derived form routine procedures performed for standard-of-care anti-pd-1 treatment (ao laboratory assessments, ct and fdg-pet) will be collected.


Eligibility criteria:
inclusion criteria: 1. histologically or cytological documented locally advanced or metastatic melanoma or nsclc. 2. patients must be eligible for standard treatment with anti-pd-1 antibody treatment (monotherapy or in combination with other checkpoint inhibitors). 3. age ≥18 years. 4. measurable disease, as defined by standard recist v1.1. previously irradiated lesions should not be counted as target lesions. 5. metastatic or locally advanced lesion(s) of which a histological biopsy can safely be obtained according to standard clinical care procedures. 6. ability to comply with protocol. 7. signed informed consent form. exclusion criteria: 1. malignancies other than melanoma or nsclc within 5 years prior to inclusion, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent or ductal carcinoma in situ treated surgically with curative intent). 2. treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to study inclusion. * patients who have received acute, low-dose, systemic immunosuppressant medications may be enrolled. * the use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g. fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.

Keywords: immunotherapy anti-pd1 checkpoint inhibitor
the effect of horticultural activities on physical and cognitive status, mental well-being, social participation and quality of life in individuals diagnosed with dementia

Conditions: Dementia; Horticultural Therapy; Quality of Life; Occupational Therapy; ELDERLY PEOPLE

Summary: this study aims to examine the effects of horticultural activities on the physical and cognitive status, mental well-being, social participation, and quality of life of individuals diagnosed with dementia living in nursing homes. forty individuals participated in the study. the intervention group received a 10-week horticultural activity program, conducted two days a week (one activity day and one visit day), while the control group underwent evaluations without participating in the horticultural activities. various standardized assessment tools were used to evaluate mental status, functional mobility, cognitive performance, mental well-being, social participation, and quality of life.

the objective of this study is to investigate the impact of a structured horticultural activity program on individuals diagnosed with dementia who reside in nursing homes. the study was conducted with a total of 40 participants. the intervention group participated in a 10-week horticultural activity program, held twice weekly, which included one activity session and one visit session per week. the control group did not participate in the activity program but underwent the same evaluation procedures. the assessment tools used in this study included: mini mental state examination to evaluate mental status, timed up and go test to assess functional mobility, balance, and performance, rapid mild cognitive impairment test for cognitive assessment, warwick-edinburgh mental well-being scale to measure mental well-being, social and emotional loneliness scale for adults to assess social and emotional loneliness, world health organization quality of life scale elderly module to evaluate quality of life. the study is designed to explore whether horticultural activities can be beneficial as part of occupational therapy interventions for individuals with dementia living in nursing homes.

Eligibility criteria:
inclusion criteria: residents of a nursing home age 65 years or older diagnosed with dementia mini mental state examination (mmse) score of 18 or higher exclusion criteria: orthopedic dependency requiring the use of a wheelchair diagnosed with any neurological or psychological disorder other than dementia

Keywords: dementia horticultural activity nursing homes quality of life